advertisement
Abstract #27502 Published in IGR 12-4
Cytotoxicity of prostaglandin analog eye drops preserved with benzalkonium chloride in multiple corneoconjunctival cell lines
Ayaki M; Iwasawa AClinical Ophthalmology 2010; 4: 919-924
Purpose: This study evaluated the cytotoxicity of five prostaglandin analog ophthalmic solutions on four ocular surface cell lines, ie, Chang (human conjunctiva), SIRC (rabbit cornea), RC-1 (rabbit cornea), and BCE C/D-1b (bovine cornea). Methods: Cell viability was measured by neutral red and MTT assays in cells treated for 10, 30, or 60 minutes with various doses of prostaglandins (undiluted, and 2- and 10-fold dilutions). The number of cell lines with viability (greater-than or equal to)50% in the presence of selected dilution of the drug (CVS(50)) was used for comparison. In addition, 24 cell viability comparisons (four cell lines, two assays, and three exposure times) were made between latanoprost (Xalatan((registered trademark))) and each other solution at each dose. A comparison between the newly introduced tafluprost (Tapros((registered trademark))) with 0.01% benzalkonium chloride was also made. Results: The order of cell viability determined by CVS(50) was Travatan Z((registered trademark)) (travoprost with the SofZia system). Tapros (greater-than or equal to) Travatan((registered trademark)) (travoprost) = Xalatan. Rescula((registered trademark)) (unoproston). This was consistent with the results of direct comparisons between Xalatan and the other drugs. There was no clear difference in cell viability between Tapros and benzalkonium chloride. Conclusions: Use of two assays, multiple cell lines, and various dilutions and exposure times provided a unique evaluation of cytotoxicity among ophthalmic solutions. CVS(50) was useful for comparison of the cell viability of the solutions. (copyright) 2010 Ayaki and Iwasawa.
M. Ayaki. Department of Ophthalmology, Saitama National Hospital, 2-1 Suwa, Wako City, 3510102 Saitama, Japan. mayaki@olive.ocn.ne.jp
Classification:
11.16 Vehicles, delivery systems, pharmacokinetics, formulation (Part of: 11 Medical treatment)
2.1 Conjunctiva (Part of: 2 Anatomical structures in glaucoma)
11.4 Prostaglandins (Part of: 11 Medical treatment)
